These findings are in agreement with our pooled data showing increased endocrine toxicity with anti-PD-L1 agents in urothelial cancer (OR: 6.23) and pembrolizumab in NSCLC (OR: 2.78), but also improved survival outcomes in patients experiencing endocrine irAEs (HR for OS: 0.60; HR for PFS: 0.61). The gene discussed is CD274; the disease is non-small cell lung carcinoma.